Literature DB >> 16860376

Roles for fructose-2,6-bisphosphate in the control of fuel metabolism: beyond its allosteric effects on glycolytic and gluconeogenic enzymes.

Chaodong Wu1, Salmaan A Khan, Li-Jen Peng, Alex J Lange.   

Abstract

Fructose-2,6-bisphosphate (F26P2) was identified as a regulator of glucose metabolism over 25 years ago. A truly bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6PFK2/FBP2), with two active sites synthesizes F26P2 from fructose-6-phosphate (F6P) and ATP or degrades F26P2 to F6P and Pi. In the classic view, F26P2 regulates glucose metabolism by allosteric effects on 6-phosphofructo-1-kinase (6PFK1, activation) and fructose-1,6-bisphosphatase (FBPase, inhibition). When levels of F26P2 are high, glycolysis is enhanced and gluconeogenesis is inhibited. In this regard, altering levels of F26P2 via 6PFK2/FBP2 overexpression has been used for metabolic modulation, and has been shown capable of restoring euglycemia in rodent models of diabetes. Recently, a number of novel observations have suggested that F26P2 has much broader effects on the enzymes of glucose metabolism. This is evidenced by the effects of F26P2 on the gene expression of two key glucose metabolic enzymes, glucokinase (GK) and glucose-6-phosphatase (G6Pase). When levels of F26P2 are elevated in the liver, the gene expression and protein amount of GK is increased whereas G6Pase is decreased. These coordinated changes in GK and G6Pase protein illustrate how F26P2 regulates glucose metabolism. F26P2 also affects the gene expression of enzymes related to lipid metabolism. When F26P2 levels are elevated in liver, the expression of two key lipogenic enzymes, acetyl-CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS) is reduced, contributing to a unique coordinated decrease in lipogenesis. When combined, F26P2 effects on glucose and lipid metabolism provide cooperative regulation of fuel metabolism. The regulatory roles for F26P2 have also expanded to transcription factors, as well as certain key proteins (enzymes) of signaling and/or energy sensoring. Although some effects may be secondary to changes in metabolite levels, high levels of F26P2 have been shown to regulate protein amount and/or phosphorylation state of hepatic nuclear factor 1-alpha (HNF1alpha), carbohydrate response element binding protein (ChREBP), peroxisome proliferators-activated receptor alpha (PPARalpha), and peroxisome proliferators-activated receptor gamma co-activator 1beta (PGC1beta), as well as Akt and AMP-activated protein kinase (AMPK). Importantly, changes in these transcription factors, signaling proteins, and sensor proteins are produced in a way that appropriately coordinates whole body fuel metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860376     DOI: 10.1016/j.advenzreg.2006.01.010

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  23 in total

1.  Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Noelia Rivera; Jose Irimia-Dominguez; Ben Farmer; Doss W Neal; Margaret Lautz; E Patrick Donahue; Catalina M Meyer; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

2.  A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.

Authors:  Yunhua L Muller; Paolo Piaggi; Robert L Hanson; Sayuko Kobes; Shujera Bhutta; Maryam Abdussamad; Tennille Leak-Johnson; Matthias Kretzler; Ke Huang; E Jennifer Weil; Robert G Nelson; William C Knowler; Clifton Bogardus; Leslie J Baier
Journal:  Hum Mol Genet       Date:  2015-02-06       Impact factor: 6.150

3.  Crystal structure of heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) and the inhibitory influence of citrate on substrate binding.

Authors:  Robert B Crochet; Jeong-Do Kim; Herie Lee; Young-Sun Yim; Song-Gun Kim; David Neau; Yong-Hwan Lee
Journal:  Proteins       Date:  2016-11-29

4.  Effects of chronic hyperinsulinemia on metabolic pathways and insulin signaling in the fetal liver.

Authors:  Paul J Rozance; Amanda K Jones; Stephanie L Bourque; Angelo D'Alessandro; William W Hay; Laura D Brown; Stephanie R Wesolowski
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-08-24       Impact factor: 4.310

5.  Gene expression profiling elucidates a specific role for RARgamma in the retinoic acid-induced differentiation of F9 teratocarcinoma stem cells.

Authors:  Dan Su; Lorraine J Gudas
Journal:  Biochem Pharmacol       Date:  2007-11-22       Impact factor: 5.858

6.  Identification of Novel Metabolic Proteins Released by Insulin Signaling of the Rat Hypothalmus Using Liquid Chromatography-Mass Spectrometry (LC-MS).

Authors:  Chur Chin
Journal:  J Korean Neurosurg Soc       Date:  2007-12-20

7.  Genome Analysis of the Fruiting Body-Forming Myxobacterium Chondromyces crocatus Reveals High Potential for Natural Product Biosynthesis.

Authors:  Nestor Zaburannyi; Boyke Bunk; Josef Maier; Jörg Overmann; Rolf Müller
Journal:  Appl Environ Microbiol       Date:  2016-01-15       Impact factor: 4.792

8.  Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.

Authors:  Abdullah Yalcin; Brian F Clem; Alan Simmons; Andrew Lane; Kristin Nelson; Amy L Clem; Erin Brock; Deanna Siow; Binks Wattenberg; Sucheta Telang; Jason Chesney
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

9.  Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator).

Authors:  Hua Li; Gerwald Jogl
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

10.  Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer.

Authors:  Zhen Xing; Yanyan Zhang; Ke Liang; Liang Yan; Yu Xiang; Chunlai Li; Qingsong Hu; Feng Jin; Vasanta Putluri; Nagireddy Putluri; Cristian Coarfa; Arun Sreekumar; Peter K Park; Tina K Nguyen; Shouyu Wang; Jianwei Zhou; Yan Zhou; Jeffrey R Marks; David H Hawke; Mien-Chie Hung; Liuqing Yang; Leng Han; Haoqiang Ying; Chunru Lin
Journal:  Cancer Res       Date:  2018-07-02       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.